- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04972422
A Phase 1b Study of ZN-c3 in Chinese Subjects
A Phase 1b Study of ZN-c3 as a Single Agent in Patients With Solid Tumors
Study Overview
Detailed Description
This study consists of Dose Escalation and Dose Expansion component in Chinese subjects with solid tumors, described briefly as follows:
Dose Escalation: Single Agent Dose Escalation of ZN-c3 in solid tumors.
Dose Expansion: Single Agent ZN-c3 in solid tumors at the RP2D dose level.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Xu Li, M.Sc
- Phone Number: +86 15902153353
- Email: xli@zenteratx.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Fudan University Zhongshan Hospital
-
Contact:
- Tianshu Liu, MD
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- Sichuan University Huaxi Hospital
-
Contact:
- Yongsheng Wang
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Sir Run Run Shaw Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of written informed consent prior to initiation of any study-related procedures that are not considered standard of care.
- Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of informed consent.
Adequate hematologic and organ function as defined by the following criteria:
- ANC ≥ 1.5 × 109/L; excluding measurements obtained within 7 days after daily administration of filgrastim/sargramostim or within 3 weeks after administration of pegfilgrastim.
- Platelet count ≥ 100 × 109/L; excluding measurements obtained within 3 days after transfusion of platelets.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastases, AST and ALT ≤ 5 x ULN.
- Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.
- Female subjects of childbearing potential must have a negative serum beta human chorionic gonadotropin test.
- Male subjects and female subjects of childbearing potential must agree to use an effective method of contraception per institutional standard prior to the first dose and for 90 days after the last dose of ZN-c3.
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- Willingness to practice adequate sun protection (use of sunscreen or sun-protective clothing or limitation of sun exposure).
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Subjects must have a solid tumor with advanced or metastatic disease, refractory to standard therapy or for whom no standard therapy is available, or the subject is ineligible for standard therapy(ies).
- Measurable or evaluable disease per RECIST version 1.1.
- Subjects with advanced or metastatic disease, refractory to standard therapy or for whom no standard therapy is available, or the subject is ineligible for standard therapy(ies).
Exclusion Criteria:
Any of the following treatment interventions within the specified time frame prior to Cycle 1 Day 1:
- Major surgery within 28 days (the surgical incision should be fully healed prior to study drug administration).
- Radiation therapy within 21 days; however, if the radiation portal covered ≤ 5% of the bone marrow reserve, the subject is eligible irrespective of the end date of radiotherapy.
- Any prior systemic therapy regardless of the stop date, but the subject must have recovered to eligibility levels from prior toxicity.
- Autologous or allogeneic stem cell transplant within 3 months.
- Current use of an investigational agent that is not expected to be cleared by the first dosing of study drug or that has demonstrated to have prolonged side effects. Subjects should have recovered from the side effects to a Grade 0 or 1 (except alopecia).
A serious illness or medical condition(s) including, but not limited to, the following:
- Brain metastases that require immediate treatment or are clinically or radiologically unstable (i.e., have been stable for < 1 month). If receiving steroids, subjects must be receiving a stable to decreasing corticosteroid dose during at least 1 week before enrollment.
- Leptomeningeal disease that requires or is anticipated to require immediate treatment.
- Myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV).
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the subject inappropriate for entry into this study.
- Significant gastrointestinal abnormalities, including an inability to take oral medication, requirement for IV alimentation, active peptic ulcer, chronic diarrhea or vomiting considered to be clinically significant in the judgment of the Investigator, or prior surgical procedures affecting absorption.
- Active or uncontrolled infection. Subjects with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥ 72 hours.
- Unresolved toxicity of Grade > 1 attributed to any prior therapies (excluding Grade 2 neuropathy, alopecia or skin pigmentation).
- Prior therapy with ZN-c3 or known hypersensitivity to any drugs similar to ZN c3 in class.
- Prior therapy with a WEE1 inhibitor.
- Pregnant or lactating females (including the cessation of lactation) or females of childbearing potential who have a positive serum pregnancy test within 14 days prior to Cycle 1 Day 1.
- Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
- Individuals who are judged by the Investigator to be unsuitable as study subjects.
- 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of > 450 msec, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
- History or current evidence of congenital long QT syndrome.
- Administration of strong and moderate CYP3A4 inhibitors and inducers as well as strong and moderate P-gp inhibitors.
- Patients with active HBV and HCV infection: HBV DNA is higher than the upper limit of reference value if anti-HBC positive, HCV virus copy number exceeds the lower limit of detection method.
- A known history of human immunodeficiency virus infection or serum anti-HIV positive.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Agent Dose Escalation
Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
|
ZN-c3 is a study drug
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of adverse events (AEs)
Time Frame: Until 30 days after the last dose of study drug
|
Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
|
Until 30 days after the last dose of study drug
|
Incidence and severity of dose-limiting toxicities (DLTs) in DLT evaluable subjects during Cycle 1
Time Frame: At the end of Cycle 1 (each cycle is 21 days)
|
At the end of Cycle 1 (each cycle is 21 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- c3ZTCN100
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
Clinical Trials on ZN-c3
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary... and other conditionsUnited States
-
K-Group Alpha, Inc., a wholly owned subsidiary...RecruitingAcute Myeloid Leukemia (AML)United States
-
K-Group, Beta, Inc., a wholly owned subsidiary...Recruiting
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerUnited States, Australia, France, Poland
-
Joyce Liu, MDNational Cancer Institute (NCI); ZentalisNot yet recruitingUterine Cancer | Uterine Serous Carcinoma | Uterine CarcinomaUnited States
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingUterine Serous CarcinomaUnited States, Australia, Canada, Georgia
-
K-Group, Beta, Inc., a wholly owned subsidiary...PfizerRecruitingMetastatic Colorectal CancerSpain, Australia, United States, Italy, Germany, Poland, Hungary
-
K-Group, Beta, Inc., a wholly owned subsidiary...Active, not recruitingOsteosarcomaUnited States, France
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingOvarian Cancer | Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal CarcinomaUnited States, France
-
The Netherlands Cancer InstituteNot yet recruitingMetastatic Colorectal Cancer